TNF and hematologic disorder: While the role of medical therapy, including thiopurines and Tumor Necrosis Factor (TNF)-α Inhibitors (TNFi), as a risk factor for hematological malignancy is supported by recent data, it remains unclear whether the disease itself poses a risk of developing these tumors.